HRAS Polyclonal antibody
HRAS Polyclonal Antibody for WB, IP, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, rat
Applications
WB, IP, ELISA
Conjugate
Unconjugated
Cat no : 15531-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | HeLa cells, PC-12 cells, MCF-7 cells |
Positive IP detected in | HeLa cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:1000 |
Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
WB | See 2 publications below |
Product Information
15531-1-AP targets HRAS in WB, IP, ELISA applications and shows reactivity with human, rat samples.
Tested Reactivity | human, rat |
Cited Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | HRAS fusion protein Ag7704 |
Full Name | v-Ha-ras Harvey rat sarcoma viral oncogene homolog |
Calculated Molecular Weight | 21 kDa |
Observed Molecular Weight | 21 kDa |
GenBank Accession Number | BC006499 |
Gene Symbol | HRAS |
Gene ID (NCBI) | 3265 |
RRID | AB_2878147 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
Product Specific Protocols | |
---|---|
WB protocol for HRAS antibody 15531-1-AP | Download protocol |
IP protocol for HRAS antibody 15531-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Mol Med Rep Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma. | ||
Naunyn Schmiedebergs Arch Pharmacol The potential mechanism of Neu5Gc inducing colorectal cancer based on network pharmacology and experimental validation |